Belite Bio, Inc
Belite Bio, Inc (BLTE) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · BLTE · as of Jun 8, 2026
Key Statistics
Explore Belite Bio, Inc Data
blte stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 6 · Buy rate: 100.0%
The BLTE analyst consensus is Buy, based on ratings from 6 Wall Street analysts over the past 3 months. The average 12-month price target is $208.00, representing +49.81% upside from the current price of $138.84.
Competitors & Peers
blte competitorsBLTE
ACAD
ADMA
ARQT
CRNX
DYNStock Performance
Full HistoryAbout Belite Bio, Inc
Belite Bio, Inc a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and auto…
what is belite bio, inc · blte stock overview · belite bio, inc company profile · who is belite bio, inc ceo · blte NASDAQ · belite bio, inc headquarters · belite bio, inc business segments
About Stock Overview & Key Data
Belite Bio, Inc (BLTE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Apr 29, 2022. As of the latest trading session, BLTE stock price is $138.84, with a market capitalization of $5.6B. The stock has returned +133.47% over the past 12 months and -10.38% year-to-date.
According to 6 Wall Street analysts, the consensus rating for Belite Bio, Inc stock is Buy, with an average 12-month price target of $208.00. In fiscal year 2025, Belite Bio, Inc reported revenue of — and net income of -$77.6M. For detailed data — including Belite Bio, Inc revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Belite Bio, Inc (BLTE) stock price is $138.84. The stock is traded on NASDAQ under the ticker symbol BLTE. The 52-week range is $56.10 – $200.00.